Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4286924 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| Hydrochloric Acid SCHEMBL1268501 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL9865701 | 0.88 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| Hydrochloric Acid SCHEMBL8615154 | 0.86 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL9081971 | 0.86 | HRH1 (0.53) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL1743337 | 0.85 | HRH1 (0.56) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL3063913 | 0.83 | — | — | |
| SCHEMBL7208033 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL127882 | 0.80 | EHMT2 (0.59) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL29371176 | 0.80 | EHMT2 (0.59) | ALDH1A1KMT2AMAPTEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| CN-109310654-A | Particle comprising sulfur-containing compound | 诺瓦生命科学有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
| EP-2488544-B1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | UNIV MONASH (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-5733523-A | ANTITUMOR | AKZO NOBEL N.V. (NL) | 1998-03-31 | — | — | US | disclosed |
| EP-0744894-A1 | SELF-ASSEMBLING MULTIMERIC NUCLEIC ACID CONSTRUCTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5561043-A | GENETIC ENGINEERING | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0492178-B1 | Naphthoic acid derivative | FUJIREBIO KK (JP) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995020320-A1 | SELF-ASSEMBLING MULTIMERIC NUCLEIC ACID CONSTRUCTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1995-08-03 | — | — | WO | disclosed |
| US-5324728-A | Lipoxygenase inhibiting antiallergens | FUJIREBIO INC. (JP) | 1994-06-28 | — | — | US | disclosed |
| EP-0492178-A2 | Naphthoic acid derivative | FUJIREBIO INC. (JP) | 1992-07-01 | — | — | EP | disclosed |
| EP-0490434-A1 | Labelled, modified oligonucleotides | Akzo Nobel N.V. (NL) | 1992-06-17 | — | — | EP | disclosed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | ALDH1A1 1612/4885KMT2A 3161/4885MAPT 3661/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | ALDH1A1 1612/4885KMT2A 3161/4885MAPT 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.